IV Glutathione for Parkinson's Disease: Study Review

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

High-dose intravenous vitamin C (IVC) shows potential as an anti-cancer agent and an adjuvant treatment, according to a 2021 review by Franziska Böttger et al. [https://pubmed.ncbi.nlm.nih.gov/34717701/].
Early clinical trials have confirmed the safety of IVC and indicated its efficacy against various cancer types.
IVC can act synergistically with many standard chemo-therapies, and may also help reduce chemotherapy's toxic side-effects.
As of May 2021, 71 pre-clinical in vitro and in vivo studies investigated 59 anti-cancer agents combined with high-dose vitamin C, showing synergy, enhanced efficacy, or reduced toxicity [https://pubmed.ncbi.nlm.nih.gov/34717701/].

High-dose intravenous vitamin C (IVC) has emerged as a promising area of research in cancer treatment. Mounting evidence from pre-clinical studies and early-phase clinical trials suggests that IVC can act as a potent anti-cancer agent, directly targeting tumor cells and supporting the body's natural defenses. For instance, a comprehensive 2021 review by Franziska Böttger and colleagues highlighted IVC's diverse effects, including its role as a pro-oxidative cytotoxic agent, an epigenetic regulator, and an immune modulator [https://pubmed.ncbi.nlm.nih.gov/34717701/]. Beyond its direct effects, IVC also shows significant potential as an adjuvant therapy, meaning it can be used alongside standard treatments like chemotherapy. When combined with conventional anti-cancer agents, IVC has demonstrated synergistic effects and the ability to mitigate the toxic side-effects often associated with chemotherapy. Despite these promising findings, which include analyses of 20 in vitro and 4 in vivo studies on high-dose vitamin C's anti-cancer properties, researchers emphasize the critical need for more robust clinical data and large-scale phase III studies to fully establish its role in cancer care [https://pubmed.ncbi.nlm.nih.gov/34717701/].

What is High-Dose Intravenous Vitamin C (IVC)?

High-dose intravenous vitamin C, often referred to as IVC, involves administering vitamin C directly into the bloodstream at concentrations much higher than what can be achieved through oral intake. This method bypasses the digestive system, allowing for significantly elevated levels of the vitamin in the body. Vitamin C, known scientifically as ascorbic acid (AA), is a weak sugar acid that shares structural similarities with glucose. Its fundamental role in the body revolves around its capacity as an electron donor, which underpins all its known physiological and biochemical functions.

The Dual Nature of Vitamin C: Antioxidant and Pro-oxidant

The way vitamin C behaves in the body is complex and concentration-dependent. At low concentrations, typical of dietary intake, vitamin C functions primarily as a powerful antioxidant. This means it helps to neutralize harmful free radicals, protecting cells from oxidative stress and damage. This antioxidant property is well-established and contributes to many of vitamin C's general health benefits, such as supporting immune function and collagen synthesis. However, when administered intravenously in high doses, vitamin C's role shifts dramatically. At these elevated concentrations, ascorbic acid readily undergoes pH-dependent autoxidation, a process that leads to the creation of hydrogen peroxide (H2O2). This transformation turns vitamin C into a pro-oxidant.

This pro-oxidant characteristic is crucial to its potential anti-cancer effects. Hydrogen peroxide is a reactive oxygen species that, when produced in high amounts, can be selectively toxic to cancer cells while largely sparing healthy cells. Cancer cells often have impaired antioxidant defense systems compared to normal cells, making them more vulnerable to oxidative stress induced by high levels of H2O2. The selective toxicity of high-dose IVC is a key area of ongoing research and helps explain how this seemingly simple molecule can have such a profound impact in pre-clinical studies. The shift from antioxidant to pro-oxidant depends on the concentration achieved in the bloodstream, emphasizing why intravenous administration is necessary for therapeutic effects in cancer. Understanding this dual nature of vitamin C is fundamental to grasping its potential in oncology.

Administration and Dosage Considerations

Administering high-dose IVC requires careful consideration of the specific concentration and frequency to achieve therapeutic effects. The research distinguishes between different dose levels based on how vitamin C is delivered and its concentration. For instance, in vitro studies often refer to high doses as being greater than or equal to 1 millimolar (mM), while in vivo (animal) and clinical studies define high doses as 1 gram per kilogram (g/kg) or more. Medium doses are typically around 0.5 mM in vitro, and low doses are less than or equal to 0.1 mM in vitro, or less than 1 g/kg in vivo, or a whole body dose of 10 grams or less in clinical settings. These distinctions are critical because the pro-oxidant effect, which is believed to be key for anti-cancer activity, requires these higher concentrations. The solvent used for vitamin C preparation is also noted in studies, with water (including MiliQ water, demi water, and sterile water) being a common choice. The precise dosing protocols and administration frequencies vary across studies, reflecting the ongoing exploration into optimizing IVC therapy.

The structural relationship between ascorbic acid and glucose is also important. Cancer cells often exhibit increased glucose metabolism, a phenomenon known as the Warburg effect. Because vitamin C shares structural similarities with glucose, cancer cells may mistakenly take up large amounts of ascorbic acid through glucose transporters. Once inside the cancer cell, the high concentration of ascorbic acid can then generate hydrogen peroxide, leading to oxidative stress and cell death. This selective uptake mechanism contributes to the targeted action of high-dose IVC against malignant cells. The ability of vitamin C to function as both an electron donor and, at high concentrations, a producer of hydrogen peroxide, makes it a unique molecule with potential clinical benefits that are still being fully explored.

Does IVC Show Promise as an Anti-Cancer Agent?

Yes, high-dose intravenous vitamin C (IVC) shows considerable promise as a strong anti-cancer agent, according to a growing body of research. This potential stems from its ability to target cancer cells through multiple mechanisms, distinguishing it from conventional therapies that often focus on a single pathway. Early phase clinical trials have already provided encouraging results, confirming the safety of IVC administration and suggesting its efficacy in eradicating tumor cells across various cancer types.

Evidence from Pre-Clinical and Early Clinical Trials

A significant 2021 review by Franziska Böttger et al. thoroughly examined pre-clinical and clinical studies involving high-dose IVC as an anti-cancer agent [https://pubmed.ncbi.nlm.nih.gov/34717701/]. This review highlighted that mounting evidence indicates IVC's potential as a potent anti-cancer agent when delivered intravenously and in high concentrations. The findings from these early trials are crucial because they lay the groundwork for understanding how IVC might fit into future cancer treatment protocols. The safety profile observed in these early phases is particularly important, as many conventional cancer treatments come with severe side effects. The review indicated that IVC's efficacy in eliminating tumor cells has been observed in various cancer types, suggesting a broad applicability rather than being limited to just one or two specific malignancies.

The multi-targeting effects of vitamin C have been extensively unraveled in recent years, demonstrating its diverse roles in fighting cancer. As outlined in the 2021 review, IVC acts as a cancer-specific, pro-oxidative cytotoxic agent. This means it can selectively induce oxidative stress and cell death in cancer cells, largely sparing healthy tissues. Beyond this direct cytotoxic action, IVC also functions as an anti-cancer epigenetic regulator. Epigenetics refers to changes in gene expression that do not involve alterations to the underlying DNA sequence, and IVC's ability to influence these processes can help to reprogram cancer cells towards a less aggressive state. Furthermore, IVC acts as an immune modulator, boosting the body's own immune response against cancer. These combined mechanisms make IVC a multifaceted agent, capable of attacking cancer from several angles simultaneously.

Molecular Mechanisms and Cellular Impact

The intricate ways in which high-dose IVC impacts cancer cells at a molecular level are continually being uncovered. The 2021 review specifically focused on global molecular profiling studies, including transcriptomics, proteomics, and metabolomics, to provide an elaborate overview of the mechanisms involved [https://pubmed.ncbi.nlm.nih.gov/34717701/]. These "omics" studies help researchers understand changes in gene activity, protein expression, and metabolic pathways within cancer cells when exposed to IVC. For example, the review documented 20 in vitro and 4 in vivo studies that contributed to this molecular understanding, illustrating the depth of research into how IVC works [https://pubmed.ncbi.nlm.nih.gov/34717701/]. This level of detail is critical for developing targeted therapies and predicting which cancer types might respond best to IVC. For more details, see High-dose IVC as a multi-targeting agent in cancer treatment.

The concept of high-dose vitamin C as a metabolic treatment of cancer represents a new dimension in the era of adjuvant and intensive therapy. The understanding that vitamin C, a weak sugar acid structurally related to glucose, can impact the metabolism of cancer cells is central to its therapeutic potential. This metabolic influence is tied to the Warburg effect, a phenomenon where cancer cells preferentially use glycolysis for energy, even in the presence of oxygen. High-dose IVC, by generating hydrogen peroxide, can disrupt these altered metabolic pathways in cancer cells. The detailed exploration of these molecular mechanisms, as presented in the review, underscores the scientific rationale behind the use of high-dose IVC and provides a foundation for future research. Despite the promising findings, the need for more extensive awareness and further clinical validation remains a key message from the scientific community.

How Does IVC Affect Cancer Cells?

High-dose intravenous vitamin C affects cancer cells through a variety of sophisticated mechanisms, making it a multi-targeting agent in oncology. Its actions extend beyond simple cell destruction, influencing cancer cell behavior, metabolism, and the overall tumor microenvironment. This comprehensive approach to targeting cancer cells is what makes IVC a subject of intense research.

Direct Cytotoxic Effects and Metabolic Disruption

One of the primary ways high-dose IVC impacts cancer cells is through its direct cytotoxic effect. As discussed earlier, at high concentrations, vitamin C acts as a pro-oxidant, leading to the generation of hydrogen peroxide (H2O2). This H2O2 induces oxidative stress within cancer cells, which they are often less equipped to handle compared to healthy cells. In vitro results and studies conducted in mice consistently prove the cytotoxic effect of ascorbic acid on cancer cells. This means that in laboratory settings and animal models, IVC directly kills cancer cells or inhibits their growth. The selective vulnerability of cancer cells to oxidative stress is a key factor in this mechanism.

A critical aspect of IVC's cytotoxic effect is its dependence on hypoxia-induced factors. Hypoxia refers to a state of low oxygen, which is common in rapidly growing tumors due to their disorganized blood supply. Cancer cells in hypoxic regions often rely on altered metabolic pathways, such as the Warburg metabolism, to survive and proliferate. The cytotoxic effect of ascorbic acid specifically impacts these anoxic (oxygen-deprived) cells that utilize Warburg metabolism. This suggests that IVC might be particularly effective against the core of a tumor, where oxygen levels are lowest. By targeting cells with this specific metabolic profile, IVC can prevent tumor growth. However, a crucial observation from research indicates that discontinuation of this treatment can lead to the repeated expansion of the tumor, emphasizing the need for continuous or sustained therapy to maintain its anti-growth effects.

Modulating Cancer Progression and Immune Response

Beyond direct cell killing, high-dose IVC also influences several processes critical to cancer progression. It can reverse epithelial-to-mesenchymal transition (EMT), a process where epithelial cells lose their cell polarity and cell-cell adhesion and gain migratory and invasive properties, which is a hallmark of metastasis. By reversing EMT, IVC potentially reduces the ability of cancer cells to spread to other parts of the body. Additionally, IVC has been shown to inhibit hypoxia, which is the low-oxygen state within tumors that drives aggressive cancer behavior and resistance to therapy. By counteracting hypoxia, IVC can make tumor cells more susceptible to other treatments and reduce their ability to adapt to stressful conditions.

Another important mechanism involves the inhibition of oncogenic kinase signaling. Kinases are enzymes that play a crucial role in regulating cell growth, division, and survival. When these signaling pathways become dysregulated, they can drive uncontrolled cancer cell proliferation. IVC's ability to inhibit these signals can therefore help to slow down tumor growth and progression. Importantly, high-dose IVC also boosts the immune response, turning the body's own defense system into a more effective weapon against cancer. This immune-modulating effect can enhance the ability of immune cells to recognize and destroy cancer cells, contributing to a more comprehensive anti-cancer strategy. The detailed mechanisms behind these effects have been explored in pre-clinical studies, which showed effects across various cancer types. Some analyses included 20 in vitro and 4 in vivo studies, providing a robust foundation for understanding these complex interactions [https://pubmed.ncbi.nlm.nih.gov/34717701/]. This multi-pronged attack on cancer cells—cytotoxicity, metabolic disruption, anti-metastatic action, and immune modulation—positions high-dose IVC as a highly promising agent in the fight against cancer.

Can IVC Work with Standard Cancer Treatments?

Yes, high-dose intravenous vitamin C (IVC) shows significant potential to work effectively with standard cancer treatments, acting as a powerful adjuvant therapy. Adjuvant therapy refers to treatments given in addition to the primary treatment, often to enhance its effectiveness or reduce side effects. Research indicates that IVC can act synergistically with many conventional chemotherapy treatments, meaning their combined effect is greater than the sum of their individual effects.

Synergistic Effects with Chemotherapy

The idea that high-dose IVC can enhance the efficacy of chemotherapy is a critical area of investigation. When used as an adjuvant treatment for cancer, IVC has demonstrated its ability to work synergistically with many standard (chemo-) therapies. This synergy can lead to more effective tumor eradication and potentially overcome resistance mechanisms that cancer cells might develop against chemotherapy drugs. The underlying mechanisms for this synergy are complex but may involve IVC increasing the oxidative stress within cancer cells, making them more vulnerable to the cytotoxic effects of chemotherapy. By creating an environment where cancer cells are already under stress, IVC can lower the threshold at which chemotherapy drugs become lethal to the tumor.

A comprehensive review updated in May 2021 detailed the effects of combining high-dose vitamin C with various anti-cancer agents. This review investigated 59 different anti-cancer agents in a total of 71 pre-clinical in vitro and in vivo studies [https://pubmed.ncbi.nlm.nih.gov/34717701/]. The described effects included synergy, enhanced efficacy, superior or equivalent effect compared to single agents, and importantly, reduced toxicity. This extensive body of pre-clinical work provides strong evidence that IVC can be a valuable addition to existing treatment protocols. The studies explored various combinations, demonstrating the versatility of IVC as a co-treatment. The success observed in these pre-clinical settings suggests that IVC could potentially improve treatment outcomes for patients undergoing chemotherapy, either by making the primary treatment more effective or by making it more tolerable. For more details, see Vitamin C treatment effectiveness in cancer patients.

Mitigating Toxic Side-Effects

Beyond enhancing efficacy, one of the most compelling aspects of high-dose IVC as an adjuvant treatment is its potential to mitigate the toxic side-effects of chemotherapy. Chemotherapy drugs, while effective at killing cancer cells, often cause severe side effects because they also damage healthy, rapidly dividing cells in the body. These side effects can include nausea, fatigue, hair loss, nerve damage (neuropathy), and bone marrow suppression. The ability of IVC to potentially reduce these adverse effects could significantly improve the quality of life for cancer patients during treatment. The 2021 review mentioned that some combinations of IVC with anti-cancer agents showed reduced toxicity, which is a major benefit [https://pubmed.ncbi.nlm.nih.gov/34717701/].

The mechanisms by which IVC might reduce chemotherapy toxicity are still being investigated but could involve its antioxidant properties in healthy cells (at physiological concentrations) or its ability to support detoxification pathways. By protecting healthy cells from chemotherapy-induced damage, IVC could allow patients to tolerate higher doses of chemotherapy or complete their treatment cycles with fewer interruptions. This could lead to better overall treatment adherence and outcomes. The finding that IVC can enhance efficacy while simultaneously reducing toxicity makes it a particularly attractive candidate for adjuvant therapy. This dual benefit—improving the effectiveness of standard treatments while lessening their harsh impact on the patient—underscores the need for further clinical research to fully integrate high-dose IVC into conventional cancer care.

What Are the Current Clinical Findings and Limitations?

While pre-clinical data and early-phase clinical trials offer a promising outlook for high-dose intravenous vitamin C (IVC) in cancer treatment, the current clinical evidence for its therapeutic effect remains ambiguous. This ambiguity highlights a significant gap between laboratory findings and definitive patient outcomes, underscoring the complexities of translating promising research into standard medical practice.

Ambiguity in Clinical Evidence

A detailed 2022 analysis by János Hunyady reviewed 20 publications specifically related to high-dose intravenous vitamin C therapy (HAAT) [https://pubmed.ncbi.nlm.nih.gov/35457200/]. This analysis, which synthesized results from four review articles and information from the National Cancer Institute, suggests that HAAT might be a useful cancer-treating tool under specific circumstances. However, the overall conclusion points to an ambiguous therapeutic effect. This means that while some studies show positive results, others may not be as conclusive, or the benefits might be observed only in particular patient populations or cancer types. The difference between the consistent cytotoxic effects seen in in vitro results and murine experiments, and the mixed clinical evidence, might be caused by a missing knowledge of ascorbic acid's actions in the complex human body. This gap in understanding underscores the need for more targeted and rigorous clinical investigations.

The review also noted that the cytotoxic effect of ascorbic acid is hypoxia-induced factor dependent, impacting only anoxic cells that utilize Warburg metabolism [https://pubmed.ncbi.nlm.nih.gov/35457200/]. This specificity suggests that HAAT might be more effective against certain tumor characteristics, potentially explaining why its overall clinical efficacy appears ambiguous when applied broadly. Furthermore, the analysis highlighted a critical observation: HAAT prevents tumor growth, but discontinuing treatment leads to repeated expansion of the tumor [https://pubmed.ncbi.nlm.nih.gov/35457200/]. This finding implies that if HAAT is indeed effective, it might require continuous administration, similar to how some maintenance therapies are used in oncology. This aspect has significant implications for treatment protocols and patient adherence.

The Need for Robust Clinical Trials

Despite the strong rationale and ample pre-clinical evidence, a major limitation in the field is the lack of strong clinical data and large-scale phase III studies. Phase III trials are crucial for confirming the efficacy and safety of a new treatment in a large patient population and comparing it against existing standard therapies. Without these definitive studies, high-dose IVC cannot be widely adopted as a standard cancer treatment, regardless of how promising early findings appear. "Despite the rationale and ample evidence, strong clinical data and phase III studies are lacking. Therefore, there is a need for more extensive awareness of the use of this highly promising, non-toxic cancer treatment in the clinical setting," stated Franziska Böttger et al. in their 2021 review [https://pubmed.ncbi.nlm.nih.gov/34717701/]. This statement underscores the urgent need for more rigorous clinical research to move IVC from a promising experimental therapy to a recognized part of cancer care.

The current situation calls for a reassessment of the clinical use of HAAT in cancer treatment, as suggested by János Hunyady [https://pubmed.ncbi.nlm.nih.gov/35457200/]. This reassessment would involve designing and executing well-controlled clinical trials that can conclusively determine the conditions under which HAAT is most effective, for which cancer types, and in which patient populations. The absence of such definitive data makes it challenging for healthcare providers to recommend IVC with confidence and for regulatory bodies to approve its widespread use. The journey from promising laboratory findings to established clinical practice is long and requires substantial investment in large-scale human trials. Until these studies are completed, the full potential and precise role of high-dose intravenous vitamin C in cancer treatment will remain largely undefined.

Why is More Research Needed for IVC in Cancer Treatment?

More research is critically needed for high-dose intravenous vitamin C (IVC) in cancer treatment because, despite its significant promise and non-toxic nature, its precise role and optimal application remain undefined in clinical practice. The scientific community has identified several key areas where further investigation is essential to fully understand and leverage IVC's potential.

Bridging the Gap Between Pre-Clinical and Clinical Findings

One of the primary reasons for the urgent call for more research is the discrepancy between the consistent positive outcomes observed in pre-clinical studies (in vitro and in animal models) and the ambiguous results from current human clinical trials. While in vitro results and murine experiments consistently prove the cytotoxic effect of ascorbic acid on cancer cells, current clinical evidence for high-dose intravenous vitamin C's therapeutic effect is ambiguous. This difference might be caused by the missing knowledge of AA's actions in the complex physiological environment of humans. The human body's intricate systems, including metabolism, immune response, and tumor heterogeneity, can influence how IVC is absorbed, distributed, and acts on cancer cells in ways that are not fully captured in simpler laboratory models. For instance, factors like individual patient variability, genetic makeup, and the specific characteristics of different tumors could all play a role in how effectively IVC works. For more details, see Systematic review of Intravenous Vitamin C and Cancer.

Therefore, more study results on high-dose intravenous vitamin C therapy (HAAT) are desperately needed to clarify its actions and the specific conditions under which it is most effective. This includes understanding the optimal dosing regimens, infusion frequencies, and duration of treatment. Researchers need to identify biomarkers that can predict which patients are most likely to respond to IVC, allowing for more personalized and effective treatment strategies. Without this deeper understanding, the full clinical potential of IVC remains untapped. The call for more research is not a dismissal of IVC's potential but rather a recognition that rigorous scientific inquiry is necessary to translate promising findings into reliable clinical applications.

Establishing Clinical Efficacy and Safety

There is a clear and pressing need for strong clinical data, particularly from large-scale phase III studies, to conclusively establish the efficacy and safety of high-dose IVC as a cancer treatment. As Franziska Böttger et al. highlighted, "Despite the rationale and ample evidence, strong clinical data and phase III studies are lacking. Therefore, there is a need for more extensive awareness of the use of this highly promising, non-toxic cancer treatment in the clinical setting" [https://pubmed.ncbi.nlm.nih.gov/34717701/]. These large-scale trials are essential for several reasons. They can provide statistically significant evidence of benefit, compare IVC against placebo or standard care, identify potential long-term side effects, and determine the optimal patient populations for treatment. Without phase III studies, it is challenging for IVC to gain widespread acceptance in conventional oncology and for regulatory bodies to approve its use for specific cancer indications.

Furthermore, the observation that the cytotoxic effect of ascorbic acid is hypoxia-induced factor dependent and impacts only anoxic cells using Warburg metabolism suggests a need for research into how to identify and target these specific tumor characteristics in patients [https://pubmed.ncbi.nlm.nih.gov/35457200/]. Imaging techniques or biopsy analyses could potentially help identify tumors with these metabolic profiles, allowing for more precise patient selection. The finding that discontinuation of HAAT leads to repeated expansion of the tumor also necessitates studies on maintenance therapy or combination strategies that can sustain the anti-tumor effects [https://pubmed.ncbi.nlm.nih.gov/35457200/]. In summary, while the foundation of pre-clinical research is robust, the journey to integrate high-dose IVC into standard cancer care requires a significant investment in well-designed, large-scale clinical trials that address the current ambiguities and provide definitive answers regarding its clinical utility.

Frequently Asked Questions

Is IV Vitamin C safe for cancer patients?

Yes, early phase clinical trials have generally confirmed the safety of high-dose intravenous vitamin C (IVC) for cancer patients. A 2021 review by Franziska Böttger et al. stated that "Early phase clinical trials have confirmed safety" of IVC in cancer treatment [https://pubmed.ncbi.nlm.nih.gov/34717701/]. However, as with any medical treatment, safety can depend on individual patient health, specific cancer type, and other co-administered therapies. Patients should always consult with a qualified healthcare provider to discuss their specific situation.

How does high-dose IV Vitamin C kill cancer cells?

High-dose IV Vitamin C primarily kills cancer cells by acting as a pro-oxidant, generating hydrogen peroxide (H2O2) within the cells. This oxidative stress is selectively toxic to cancer cells because they often have impaired antioxidant defense systems. A 2022 analysis by János Hunyady explained that "The AA's cytotoxic effect is hypoxia-induced factor dependent. It impacts only the anoxic cells, using the Warburg metabolism," suggesting a targeted action against specific cancer cell characteristics [https://pubmed.ncbi.nlm.nih.gov/35457200/]. Additionally, IVC can interfere with cancer cell metabolism, inhibit growth signals, and boost the immune response.

Can IV Vitamin C be used with chemotherapy?

Yes, high-dose IV Vitamin C shows strong potential as an adjuvant treatment that can be used with chemotherapy. It can act synergistically with many standard chemotherapy treatments, enhancing their efficacy. Furthermore, IVC may help mitigate the toxic side-effects of chemotherapy, potentially improving patient tolerance. A 2021 review described that 71 pre-clinical in vitro and in vivo studies investigated 59 anti-cancer agents combined with high-dose vitamin C, showing synergy, enhanced efficacy, or reduced toxicity [https://pubmed.ncbi.nlm.nih.gov/34717701/].

What types of cancer have been studied with IV Vitamin C?

High-dose IV Vitamin C has been studied across various cancer types in pre-clinical and early clinical trials. The 2021 review by Böttger et al. indicated that early phase clinical trials "indicated efficacy of IVC in eradicating tumour cells of various cancer types" [https://pubmed.ncbi.nlm.nih.gov/34717701/]. While specific cancer types are detailed in the full studies, the broad statement suggests a wide range of investigations rather than a focus on a single type. More research is needed to determine precise efficacy across all cancer types.

Why isn't IV Vitamin C a standard cancer treatment yet?

IV Vitamin C is not yet a standard cancer treatment because, despite promising pre-clinical and early clinical data, strong clinical data and large-scale phase III studies are still lacking. As Franziska Böttger et al. stated, "Despite the rationale and ample evidence, strong clinical data and phase III studies are lacking" [https://pubmed.ncbi.nlm.nih.gov/34717701/]. These definitive studies are essential to conclusively prove its efficacy, safety, and optimal use compared to existing treatments, which is a requirement for widespread adoption and regulatory approval.